Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

CJ-1: an optimized mRNA platform with enhanced protein expression and minimal immunogenicity for therapeutic applications

Gene Therapy (2026)Cite this article

Subjects

Abstract

Messenger RNA therapeutics offer broad potential across various diseases, yet achieving sustained and efficient protein expression remains a central challenge. In this study, we report CJ-1, a novel mRNA construct engineered through systematic optimization of major regulatory elements, including the 5′ and 3′ untranslated regions and poly (A) tail. CJ-1 consistently outperformed first-generation mRNA constructs in protein expression across multiple cell types and in vivo mouse models. Moreover, CJ-1 elicited markedly lower cytokine responses, indicating reduced innate immune activation. To evaluate its therapeutic applicability, erythropoietin (EPO)-encoding CJ-1 mRNA was encapsulated in a Pfizer-BioNTech lipid nanoparticle formulation and administered intraperitoneally in mice. This resulted in elevated, sustained serum EPO levels and significant increases in reticulocyte counts and hematocrit. These findings support CJ-1 as a promising mRNA platform with enhanced expression and minimal immunogenicity, advancing the development of safer and more effective mRNA-based therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Analysis of cellular and viral 3’ UTRs and mixed tails on protein expression.
Fig. 2: Analysis of the combinations of 5’ UTRs, 3’ UTRs and mixed tails on protein expression.
Fig. 3: Analysis of CJ-1 mRNA efficacy compared to reference mRNA platforms.
Fig. 4: CJ-1 mRNA induces stronger bioluminescent activity in mice compared to reference mRNAs.
Fig. 5: Enhanced EPO expression driven by the CJ-1 mRNA platform and improved hematological parameters.

Similar content being viewed by others

Data availability

The datasets generated and analyzed in this study are available from the corresponding authors upon reasonable request.

References

  1. Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today. 2019;28:100766. https://doi.org/10.1016/j.nantod.2019.100766.

    Article  CAS  Google Scholar 

  2. Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20:817–38. https://doi.org/10.1038/s41573-021-00283-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Szabó GT, Mahiny AJ, Vlatkovic I. COVID-19 mRNA vaccines: platforms and current developments. Mol Ther. 2022;30:1850–68. https://doi.org/10.1016/j.ymthe.2022.02.016.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Jahanafrooz Z, Baradaran B, Mosafer J, Hashemzaei M, Rezaei T, Mokhtarzadeh A, et al. Comparison of DNA and mRNA vaccines against cancer. Drug Discov Today. 2020;25:552–60. https://doi.org/10.1016/j.drudis.2019.12.003.

    Article  PubMed  Google Scholar 

  5. Kong B, Kim Y, Kim EH, Suk JS, Yang Y. mRNA: a promising platform for cancer immunotherapy. Adv Drug Deliv Rev. 2023;199:114993. https://doi.org/10.1016/j.addr.2023.114993.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Haghmorad D, Eslami M, Orooji N, Halabitska I, Kamyshna I, Kamyshnyi O, et al. mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy. Front Bioeng Biotechnol. 2025;13:1547025. https://doi.org/10.3389/fbioe.2025.1547025.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Zeng C, Zhang C, Walker PG, Dong Y. Formulation and delivery technologies for mRNA vaccines. In: Yu D, Petsch B, editors. mRNA vaccines. Cham: Springer International Publishing; 2022. p. 71–110.

  8. Yu M-Z, Wang N-N, Zhu J-Q, Lin Y-X. The clinical progress and challenges of mRNA vaccines. WIREs Nanomed Nanobiotechnology. 2023;15:e1894. https://doi.org/10.1002/wnan.1894.

    Article  CAS  Google Scholar 

  9. Evans JP, Zeng C, Carlin C, Lozanski G, Saif LJ, Oltz EM, et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med. 2022;14:eabn8057. https://doi.org/10.1126/scitranslmed.abn8057.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N Engl J Med. 2021;385:e84. https://doi.org/10.1056/NEJMoa2114583.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Notarte KI, Guerrero-Arguero I, Velasco JV, Ver AT, Santos de Oliveira MH, Catahay JA, et al. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: a systematic review. J Med Virol. 2022;94:2939–61. https://doi.org/10.1002/jmv.27688.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022;22:1435–43. https://doi.org/10.1016/S1473-3099(22)00345-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. SeyedAlinaghi S, Dashti M, Afzalian A, Siami H, Ghasemzadeh A, Varshochi S, et al. The immunologic outcomes and adverse events of COVID-19 vaccine booster dose in immunosuppressed people: a systematic review. Prev Med Rep. 2024;44:102778. https://doi.org/10.1016/j.pmedr.2024.102778.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144–50. https://doi.org/10.1038/s41586-023-06063-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403:632–44. https://doi.org/10.1016/S0140-6736(23)02268-7.

    Article  CAS  PubMed  Google Scholar 

  16. Rohner E, Yang R, Foo KS, Goedel A, Chien KR. Unlocking the promise of mRNA therapeutics. Nat Biotechnol. 2022;40:1586–600. https://doi.org/10.1038/s41587-022-01491-z.

    Article  CAS  PubMed  Google Scholar 

  17. Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther. 2022;7:166 https://doi.org/10.1038/s41392-022-01007-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Zhao X, Zhong Y, Wang X, Shen J, An W. Advances in circular RNA and its applications. Int J Med Sci. 2022;19:975–85. https://doi.org/10.7150/ijms.71840.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27:710–28. https://doi.org/10.1016/j.ymthe.2019.02.012.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Anderson BR, Muramatsu H, Nallagatla SR, Bevilacqua PC, Sansing LH, Weissman D, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010;38:5884–92. https://doi.org/10.1093/nar/gkq347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Henderson JM, Ujita A, Hill E, Yousif-Rosales S, Smith C, Ko N, et al. Cap 1 messenger RNA synthesis with co-transcriptional CleanCap® analog by in vitro transcription. Curr Protoc. 2021;1:e39. https://doi.org/10.1002/cpz1.39.

    Article  CAS  PubMed  Google Scholar 

  22. Zhang H, Zhang L, Lin A, Xu C, Li Z, Liu K, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature. 2023;621:396–403. https://doi.org/10.1038/s41586-023-06127-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov. 2014;13:759–80. https://doi.org/10.1038/nrd4278.

    Article  CAS  PubMed  Google Scholar 

  24. Orlandini von Niessen AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S, et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3′ UTRs identified by cellular library screening. Mol Ther. 2019;27:824–36. https://doi.org/10.1016/j.ymthe.2018.12.011.

    Article  CAS  PubMed  Google Scholar 

  25. Jin L, Zhou Y, Zhang S, Chen S-J. mRNA vaccine sequence and structure design and optimization: advances and challenges. J Biol Chem. 2025;301:108015. https://doi.org/10.1016/j.jbc.2024.108015.

    Article  CAS  PubMed  Google Scholar 

  26. Kim Y-A, Mousavi K, Yazdi A, Zwierzyna M, Cardinali M, Fox D, et al. Computational design of mRNA vaccines. Vaccine. 2024;42:1831–40. https://doi.org/10.1016/j.vaccine.2023.07.024.

    Article  CAS  PubMed  Google Scholar 

  27. Cao J, Novoa EM, Zhang Z, Chen WCW, Liu D, Choi GCG, et al. High-throughput 5′ UTR engineering for enhanced protein production in non-viral gene therapies. Nat Commun. 2021;12:4138. https://doi.org/10.1038/s41467-021-24436-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Xia X. Detailed dissection and critical evaluation of the Pfizer/BioNTech and moderna mRNA Vaccines. Vaccines. 2021;9:734.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Granados-Riveron JT, Aquino-Jarquin G. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. Biomed Pharmacother. 2021;142:111953. https://doi.org/10.1016/j.biopha.2021.111953.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Krawczyk PS, Mazur M, Orzeł W, Gewartowska O, Jeleń S, Antczak W, et al. Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines. Nature. 2025;641:984–92. https://doi.org/10.1038/s41586-025-08842-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Packer M, Gyawali D, Yerabolu R, Schariter J, White P. A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems. Nat Commun. 2021;12:6777. https://doi.org/10.1038/s41467-021-26926-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Schober GB, Story S, Arya DP. A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient. Sci Rep. 2024;14:2403. https://doi.org/10.1038/s41598-024-52685-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. England CG, Ehlerding EB, Cai W. NanoLuc: a small luciferase is brightening up the field of bioluminescence. Bioconjugate Chem. 2016;27:1175–87. https://doi.org/10.1021/acs.bioconjchem.6b00112.

    Article  CAS  Google Scholar 

  34. Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science. 1986;234:364–8.

    Article  CAS  PubMed  Google Scholar 

  35. Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108:4009–17. https://doi.org/10.1182/blood-2006-04-015024.

    Article  CAS  PubMed  Google Scholar 

  36. García-Marquina G, Zhang A, Sproviero M, Fang Y, Gardner AF, Robb GB, et al. Streamlined DNA template preparation and co-transcriptional 5′ capped RNA synthesis enabled by solid-phase catalysis. bioRxiv. 2023:2023 https://doi.org/10.1101/2023.10.28.564520.

  37. Chen T-H, Potapov V, Dai N, Ong JL, Roy B. N1-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs. Sci Rep. 2022;12:13017. https://doi.org/10.1038/s41598-022-17249-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Holcik M, Liebhaber SA. Four highly stable eukaryotic mRNAs assemble 3′ untranslated region RNA–protein complexes sharing cis and trans components. Proc Natl Acad Sci. 1997;94:2410–4. https://doi.org/10.1073/pnas.94.6.2410.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Wang Z, Kiledjian M. The poly(A)-binding protein and an mRNA stability protein jointly regulate an endoribonuclease activity. Mol Cell Biol. 2000;20:6334–41. https://doi.org/10.1128/mcb.20.17.6334-6341.2000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Tillmar L, Carlsson C, Welsh N. Control of insulin mRNA stability in rat pancreatic islets: regulatory role of a 3′-untranslated region pyrimidine-rich sequence*. J Biol Chem. 2002;277:1099–106. https://doi.org/10.1074/jbc.M108340200.

    Article  CAS  PubMed  Google Scholar 

  41. Conrad NK, Steitz JA. A Kaposi’s sarcoma virus RNA element that increases the nuclear abundance of intronless transcripts. EMBO J. 2005;24:1831–41. https://doi.org/10.1038/sj.emboj.7600662.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Paek KY, Hong KY, Ryu I, Park SM, Keum SJ, Kwon OS, et al. Translation initiation mediated by RNA looping. Proc Natl Acad Sci. 2015;112:1041–6. https://doi.org/10.1073/pnas.1416883112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Passmore LA, Coller J. Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression. Nat Rev Mol Cell Biol. 2022;23:93–106. https://doi.org/10.1038/s41580-021-00417-y.

    Article  CAS  PubMed  Google Scholar 

  44. Lim J, Kim D, Lee Y-s, Ha M, Lee M, Yeo J, et al. Mixed tailing by TENT4A and TENT4B shields mRNA from rapid deadenylation. Science. 2018;361:701–4. https://doi.org/10.1126/science.aam5794.

    Article  CAS  PubMed  Google Scholar 

  45. Owens GC, Chappell SA, Mauro VP, Edelman GM. Identification of two short internal ribosome entry sites selected from libraries of random oligonucleotides. Proc Natl Acad Sci. 2001;98:1471–6. https://doi.org/10.1073/pnas.98.4.1471.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Trainor BM, Ghosh A, Pestov DG, Hellen CUT, Shcherbik N. A translation enhancer element from black beetle virus engages yeast eIF4G1 to drive cap-independent translation initiation. Sci Rep. 2021;11:2461. https://doi.org/10.1038/s41598-021-82025-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Chulakasian S, Chang T-J, Tsai C-H, Wong M-L, Hsu W-L. Translational enhancing activity in 5′ UTR of peste des petits ruminants virus fusion gene. FEBS J. 2013;280:1237–48. https://doi.org/10.1111/febs.12115.

    Article  CAS  PubMed  Google Scholar 

  48. Song Z, Jin L, Jiao L, Yu R, Liu H, Zhang S, et al. ALC-0315 lipid-based mRNA LNP induces stronger cellular immune responses postvaccination. Mol Pharm. 2025;22:859–70. https://doi.org/10.1021/acs.molpharmaceut.4c00995.

    Article  CAS  PubMed  Google Scholar 

  49. Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control. Release. 2015;217:345–51. https://doi.org/10.1016/j.jconrel.2015.08.007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Karikó K, Muramatsu H, Keller JM, Weissman D. Increased erythropoiesis in mice injected with submicrogram quantities of Pseudouridine-containing mRNA encoding erythropoietin. Mol Ther. 2012;20:948–53. https://doi.org/10.1038/mt.2012.7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. He Z, Song D, van Zalen S, Russell JE. Structural determinants of human ζ-globin mRNA stability. J Hematol Oncol. 2014;7:35 https://doi.org/10.1186/1756-8722-7-35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Li CY, Liang Z, Hu Y, Zhang H, Setiasabda KD, Li J, et al. Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and in vivo. Mol Ther Nucleic Acids. 2022;30:300–10. https://doi.org/10.1016/j.omtn.2022.10.003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Mino T, Takeuchi O. Post-transcriptional regulation of immune responses by RNA binding proteins. Proc Jpn Acad Ser B Phys Biol Sci. 2018;94:248–58. https://doi.org/10.2183/pjab.94.017.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Wuebben C, Bartok E, Hartmann G. Innate sensing of mRNA vaccines. Curr Opin Immunol. 2022;79:102249. https://doi.org/10.1016/j.coi.2022.102249.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to Dr. Jong Heon Kim (National Cancer Institute, Republic of Korea) for providing viral IRES-encoding DNA plasmids, Dr. Hyunjoo Cha-Molstad (KRIBB, Republic of Korea) for providing mRNA-B NLuc-encoding DNA plasmid. Finally, we thank ChatGPT (https://chat.openai.com/) for assistance with English language editing. This research was supported by the National Research Council of Science & Technology (NST), funded by the Korea government (MSIT) (No. GTL24022-000); the National Research Foundation of Korea (NRF), funded by the Ministry of Science and ICT (RS-2025-00522177); the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare (RS-2023-KH134750, RS-2024-00465298); and the KRIBB Research Initiative Programs (KGM1062521); the Bio & Medical Technology Development Program of the National Research Foundation (NRF) & funded by the Korean government (MSIT) (No. RS-2022-NR067947).

Author information

Author notes

  1. Seok-Beom Yong

    Present address: Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea

  2. These authors contributed equally: Seyoung Kim, Min Ju Jo, Min Seon Jeong.

Authors and Affiliations

  1. Nucleic Acid Therapeutics Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Republic of Korea

    Seyoung Kim, Min Ju Jo, Min Seon Jeong, Minki Ha, Youngwook Ham, Jiye Hong, Daeyong Kim, Kyuha Yum, Jaewook Yeon, Seok-Beom Yong & Sungchan Cho

  2. College of Pharmacy, Chungbuk National University, Chungbuk, Republic of Korea

    Seyoung Kim, Min Ju Jo, Minki Ha & Sang-Bae Han

  3. Advanced Bioconvergence Department, KRIBB School, Korea University of Science and Technology (KUST), Daejeon, Republic of Korea

    Min Seon Jeong, Youngwook Ham, Daeyong Kim, Kyuha Yum, Jaewook Yeon & Sungchan Cho

Authors
  1. Seyoung Kim
    View author publications

    Search author on:PubMed Google Scholar

  2. Min Ju Jo
    View author publications

    Search author on:PubMed Google Scholar

  3. Min Seon Jeong
    View author publications

    Search author on:PubMed Google Scholar

  4. Minki Ha
    View author publications

    Search author on:PubMed Google Scholar

  5. Youngwook Ham
    View author publications

    Search author on:PubMed Google Scholar

  6. Jiye Hong
    View author publications

    Search author on:PubMed Google Scholar

  7. Daeyong Kim
    View author publications

    Search author on:PubMed Google Scholar

  8. Kyuha Yum
    View author publications

    Search author on:PubMed Google Scholar

  9. Jaewook Yeon
    View author publications

    Search author on:PubMed Google Scholar

  10. Sang-Bae Han
    View author publications

    Search author on:PubMed Google Scholar

  11. Seok-Beom Yong
    View author publications

    Search author on:PubMed Google Scholar

  12. Sungchan Cho
    View author publications

    Search author on:PubMed Google Scholar

Contributions

SC conceived the project and supervised all procedures of this study. SC, SK, MJJ, MSJ, and YH designed the experiments and analyzed the data. SK, MJJ, MSJ, MKH, JH, DY, KY, JY, and SBY performed the experiments and prepared the figures. SBH provided various intellectual and material support. SC, SK, MJJ, MSJ, MKH, and SBY prepared the figures and wrote the manuscript.

Corresponding author

Correspondence to Sungchan Cho.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethical approval

All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the Korea Research Institute of Bioscience and Biotechnology (KRIBB) (Approval Number: KRIBB-AEC-24299) and performed in accordance with KRIBB guidelines.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, S., Jo, M.J., Jeong, M.S. et al. CJ-1: an optimized mRNA platform with enhanced protein expression and minimal immunogenicity for therapeutic applications. Gene Ther (2026). https://doi.org/10.1038/s41434-026-00606-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41434-026-00606-4

Search

Advanced search

Quick links